Alliancebernstein L.P. Verve Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 83,450 shares of VERV stock, worth $379,697. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,450

Previous 83,450 -0.0%

Holding current value

$379,697

Previous $407,000 0.98%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $90,630 - $243,521	19,040 Added 29.56%	83,450 $407,000
Q1 2024 May 14, 2024	BUY	$10.81 - $17.96 $236,847 - $393,503	21,910 Added 51.55%	64,410 $855,000
Q3 2023 Nov 14, 2023	SELL	$11.42 - $20.82 $378,801 - $690,599	-33,170 Reduced 43.84%	42,500 $563,000
Q2 2023 Aug 15, 2023	SELL	$13.34 - $19.9 $41,354 - $61,689	-3,100 Reduced 3.94%	75,670 $1.42 Million
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $1,430 - $2,401	-100 Reduced 0.13%	78,770 $1.14 Million
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $91,035 - $207,570	5,100 Added 6.91%	78,870 $1.53 Million
Q3 2022 Nov 15, 2022	BUY	$15.63 - $41.49 $524,699 - $1.39 Million	33,570 Added 83.51%	73,770 $2.53 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $67,954 - $141,337	6,100 Added 17.89%	40,200 $614,000
Q1 2022 May 13, 2022	BUY	$20.92 - $39.36 $424,676 - $799,008	20,300 Added 147.1%	34,100 $778,000
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $70,268 - $120,604	-2,200 Reduced 13.75%	13,800 $509,000
Q3 2021 Nov 10, 2021	BUY	$46.0 - $73.99 $449,926 - $723,696	9,781 Added 157.28%	16,000 $752,000
Q2 2021 Jul 30, 2021	BUY	$31.92 - $60.25 $198,510 - $374,694	6,219 New	6,219 $375,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $273M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Verve Therapeutics, Inc. Transaction History